ClinicalTrials.gg
CompletedNCT01577160Updated Jan 14, 2014Results posted

A Study to Evaluate Flexible Dose of Paliperidone Extended Release (ER) and Clinical Response in Participants With Schizophrenia

A Phase 4 interventional study of Paliperidone ER in Schizophrenia, sponsored by Johnson & Johnson Taiwan Ltd. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-01-14.

Sponsored by Johnson & Johnson Taiwan Ltd (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
353
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
31st of 115
353 · median 178
Started
2008
with 12 others
Phase 4
42 of 115
5 open now
Registered
76th of 115
by date
Lead sponsor
4 of 115
Johnson & Johnson Taiwan Ltd

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 31st largest by enrollment, is one of 13 that started in 2008, is one of 42 in phase 4, and was the 76th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of paliperidone ER for the treatment of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) participants.

Read the detailed description

This is a multi-center (when more than one hospital or medical school team work on a medical research study), open-label (all people know the identity of the intervention), prospective (study following participants forward in time), non-comparative study. The total study duration will be 12 weeks for each participant and will include following visits: Screening, Week 2, 4, 8, and 12 (end of treatment or early withdrawal). The effectiveness of paliperidone ER will be evaluated at Week 12 by the proportion of responders who are evaluated as "very much improved" or "much improved" on the Clinical Global Impression improvement (CGI-I) Scale. Participants' safety will also be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone Extended Release (ER)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are diagnosed with schizophrenia (according to [Edition 4] criteria)
  • Participants with Clinical Global Impression-Severity (CGI-S) score greater than or equal to 4 points (moderately ill) at Screening
  • women who consented to the consistent use of the acceptable (oral contraceptive, contraceptive injection, intrauterine device, double barrier method and contraceptive patch)
  • Participants who are capable of and willing to fill out the questionnaire for themselves
  • Participants who are compliant with self-medication or can receive consistent help or support

Exclusion criteria

Exclusion Criteria:

  • Participants with the past history of neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)
  • Participants with allergy or to risperidone or paliperidone
  • Participants who have taken clozapine, or have been exposed to the study drug within one month before screening
  • Participants who have been treated with the long acting antipsychotic injection within 28 days
  • Participants with significant risk including suicide or aggressive behavior
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    Paliperidone Extended Release (ER)

    Drug: Paliperidone ER

Interventions

  • Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.

06

What researchers measure

Primary outcomes

  1. Percentage of Responders as Per Clinical Global Impression - Improvement (CGI-I) Scale

    The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. Responders were defined as participants evaluated as "1: very much improved" or "2: much improved" on the CGI-I scale at Week 12.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12

    The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.

    Time frame: Baseline, Week 12

  2. Number of Participants With Clinical Global Impression - Improvement (CGI-I) Score

    The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

    Time frame: Week 12

  3. Change From Baseline in Personal and Social Performance (PSP) Score at Week 12

    The PSP is 100-point validated clinician-rated scale that assesses degree of difficulty in 4 areas of functioning: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors rated on 6-point scale (1=absent to 6=very severe).Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning, with higher transformed score indicating better function. Total score is divided into 3 levels: 71-100 (mild difficulty); 31-70 (marked difficulty) and 1-30 (severe difficulty).

    Time frame: Baseline, Week 12

  4. Change From Baseline in Drug Attitude Inventory (DAI-10) Score at Week 12

    The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response (SR). A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive SR; a negative sum of scores indicates a negative SR (non-compliant). The final score is the grand total of the positive and negative points. Total score ranges from (-) 10 to (+) 10, higher score indicates positive SR (compliant) and lower score indicates negative SR (non-compliant).

    Time frame: Baseline, Week 12

07

Results

Posted Jan 14, 2014
Limitations and caveats
Some Adverse Events summaries were reported based on estimates due to the fact that they were not prepared in the original study report and the relevant definitions of the data elements were not available for these summaries to be regenerated.

Participant flow

Participant flow — Overall Study
MilestonePaliperidone ER
Started353
Completed255
Not completed98
Withdrew: Adverse event9
Withdrew: Lack of efficacy15
Withdrew: Lost to follow-up40
Withdrew: Withdrawal by subject18
Withdrew: Subject uncooperative7
Withdrew: Other9

Outcome measures

PrimaryPercentage of Responders as Per Clinical Global Impression - Improvement (CGI-I) Scale

The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. Responders were defined as participants evaluated as "1: very much improved" or "2: much improved" on the CGI-I scale at Week 12.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Responders as Per Clinical Global Impression - Improvement (CGI-I) Scale
percentage of participantsPaliperidone Extended Release (ER)
Percentage of Responders as Per Clinical Global Impression - Improvement (CGI-I) Scale21.6 (16.68 to 27.13)
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12

The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Week 12
units on a scalePaliperidone Extended Release (ER)
Baseline (n=331)5.0 ± 0.8
Change at Week 12 (n=255)-1.4 ± 1.0
SecondaryNumber of Participants With Clinical Global Impression - Improvement (CGI-I) Score

The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.

Time frame:
Week 12
Reported as:
Number · participants
Number of Participants With Clinical Global Impression - Improvement (CGI-I) Score
participantsPaliperidone Extended Release (ER)
Very much improved3 ± 0.9
Much improved52
Minimally improved119
No change67
Minimally worse10
Much worse2
Very much worse2
SecondaryChange From Baseline in Personal and Social Performance (PSP) Score at Week 12

The PSP is 100-point validated clinician-rated scale that assesses degree of difficulty in 4 areas of functioning: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors rated on 6-point scale (1=absent to 6=very severe).Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning, with higher transformed score indicating better function. Total score is divided into 3 levels: 71-100 (mild difficulty); 31-70 (marked difficulty) and 1-30 (severe difficulty).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Personal and Social Performance (PSP) Score at Week 12
units on a scalePaliperidone Extended Release (ER)
Baseline (n=331)42.6 ± 14.9
Change at Week 12 (n=267)14.3 ± 13.0
SecondaryChange From Baseline in Drug Attitude Inventory (DAI-10) Score at Week 12

The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. It is the binary scale assessing the participant's subjective response (SR). A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive SR; a negative sum of scores indicates a negative SR (non-compliant). The final score is the grand total of the positive and negative points. Total score ranges from (-) 10 to (+) 10, higher score indicates positive SR (compliant) and lower score indicates negative SR (non-compliant).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Drug Attitude Inventory (DAI-10) Score at Week 12
units on a scalePaliperidone Extended Release (ER)
Baseline (n=331)2.5 ± 4.6
Change at Week 12 (n=267)1.0 ± 4.9

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone ER—0/353 (0%)140/353 (39.7%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPaliperidone ER
InsomniaPsychiatric disorders56/353
ConstipationGastrointestinal disorders40/353
Extrapyramidal DisorderNervous system disorders34/353
AnxietyPsychiatric disorders25/353
NasopharyngitisInfections and infestations18/353
Upper Respiratory Tract InfectionInfections and infestations18/353
CoughRespiratory, thoracic and mediastinal disorders13/353
WoundInjury, poisoning and procedural complications9/353
HeadacheNervous system disorders9/353
DepressionPsychiatric disorders9/353

Baseline characteristics

Age, Continuous
Age, Continuous(years)Paliperidone ER
Mean41.1 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone ER
Female132
Male221
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 4 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2012
First posted
Apr 13, 2012
Start
May 2008
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Jan 14, 2014
Last update
Jan 14, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01577160
Responsible party
Sponsor
First posted
Apr 13, 2012
Start date
May 2008
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Jan 14, 2014
Last update
Jan 14, 2014

Study contacts

Johnson & Johnson Taiwan Ltd Clinical Trial
study director · Johnson & Johnson Taiwan Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion